AR036566A1 - Vacunas para vih 1 - Google Patents
Vacunas para vih 1Info
- Publication number
- AR036566A1 AR036566A1 ARP020103561A ARP020103561A AR036566A1 AR 036566 A1 AR036566 A1 AR 036566A1 AR P020103561 A ARP020103561 A AR P020103561A AR P020103561 A ARP020103561 A AR P020103561A AR 036566 A1 AR036566 A1 AR 036566A1
- Authority
- AR
- Argentina
- Prior art keywords
- fragment
- hiv
- nucleotide sequence
- epitope
- vaccines
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 4
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 101710177291 Gag polyprotein Proteins 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 101710125418 Major capsid protein Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2001/004207 WO2002024225A1 (en) | 2000-09-20 | 2001-09-20 | Use of immidazoquinolinamines as adjuvants in dna vaccination |
| GB0129604A GB0129604D0 (en) | 2001-12-11 | 2001-12-11 | Novel compounds |
| GB0206462A GB0206462D0 (en) | 2002-03-19 | 2002-03-19 | Vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036566A1 true AR036566A1 (es) | 2004-09-15 |
Family
ID=27256076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103561A AR036566A1 (es) | 2001-09-20 | 2002-09-20 | Vacunas para vih 1 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20070015721A1 (https=) |
| EP (2) | EP2322626A1 (https=) |
| JP (1) | JP4601956B2 (https=) |
| CN (1) | CN100392085C (https=) |
| AR (1) | AR036566A1 (https=) |
| AU (1) | AU2002362368B2 (https=) |
| BR (1) | BR0212619A (https=) |
| CA (1) | CA2461056A1 (https=) |
| CO (1) | CO5560591A2 (https=) |
| HU (1) | HUP0402259A3 (https=) |
| IL (1) | IL160809A0 (https=) |
| MX (1) | MXPA04002631A (https=) |
| NO (1) | NO331826B1 (https=) |
| NZ (1) | NZ531814A (https=) |
| PL (1) | PL207168B1 (https=) |
| WO (1) | WO2003025003A2 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2484044A1 (en) * | 2002-03-19 | 2003-10-02 | Powdermed Limited | Imidazoquinolineamines as adjuvants in hiv dna vaccination |
| GB0225788D0 (en) | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
| US8080642B2 (en) | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
| GB2406336A (en) * | 2003-09-24 | 2005-03-30 | Oxxon Pharmaccines Ltd | HIV Pharmaccines |
| GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
| DE102004049223A1 (de) * | 2004-10-08 | 2006-04-20 | Johannes-Gutenberg-Universität Mainz | Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung |
| AR053275A1 (es) * | 2005-05-12 | 2007-04-25 | Glaxo Group Ltd | Composicion de vacuna |
| AU2012201827B2 (en) * | 2005-05-12 | 2014-09-04 | Glaxo Group Limited | Vaccine composition |
| WO2008133663A2 (en) * | 2006-11-30 | 2008-11-06 | Government Of The United States Of America, As Represented By The Secretary, | Codon modified immunogenic compositions and methods of use |
| GB0700914D0 (en) * | 2007-01-18 | 2007-02-28 | Animal Health Inst | Polynucleotides and uses thereof |
| PL2137210T3 (pl) | 2007-03-02 | 2017-06-30 | Glaxosmithkline Biologicals Sa | Nowy sposób i kompozycje |
| JP5331105B2 (ja) | 2007-05-24 | 2013-10-30 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 凍結乾燥抗原組成物 |
| WO2009092113A2 (en) * | 2008-01-19 | 2009-07-23 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for the delivery of vaccines to disrupted epithelium |
| WO2011043830A2 (en) * | 2009-10-09 | 2011-04-14 | New York University | Methods, agents and peptides for inducing an innate immune response in hiv vaccination |
| BRPI0914507A2 (pt) * | 2009-12-23 | 2012-04-10 | Fundacao Oswaldo Cruz | vacina para lentivìrus baseada em vìrus recombinante vacinal da febre amarela |
| AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
| TR201802741T4 (tr) | 2010-05-14 | 2018-03-21 | Univ Oregon Health & Science | Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları. |
| GB201022007D0 (en) | 2010-12-24 | 2011-02-02 | Imp Innovations Ltd | DNA-sensor |
| HUE037408T2 (hu) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | CMV glikoproteinek és rekombináns vektorok |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| DK2964769T3 (en) | 2013-03-05 | 2018-12-10 | Univ Oregon Health & Science | Cytomegalovirus vectors enabling control of T cell targeting |
| EP3083618B1 (en) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| CN113528466B (zh) | 2014-07-16 | 2024-12-24 | 俄勒冈健康与科学大学 | 包含外源抗原的人巨细胞病毒 |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| JP6816031B2 (ja) | 2015-02-10 | 2021-01-20 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
| RU2722149C1 (ru) | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
| CN108474003A (zh) | 2015-11-20 | 2018-08-31 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
| US10532099B2 (en) | 2016-10-18 | 2020-01-14 | Oregon Health & Science University | Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules |
| TWI810456B (zh) | 2019-05-22 | 2023-08-01 | 美商基利科學股份有限公司 | Tlr7調節化合物及hiv疫苗之組合 |
| AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| ES2113371T3 (es) | 1989-11-16 | 1998-05-01 | Univ Duke | Transformacion de celulas epidermicas de tejidos animales con la ayuda de particulas. |
| US5697901A (en) | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5583035A (en) * | 1992-12-07 | 1996-12-10 | Bayer Aktiengesellschaft | HIV antisense expression vectors |
| US5654186A (en) | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
| DK0690732T3 (da) | 1994-01-21 | 2003-05-19 | Powderject Vaccines Inc | Gasdrevet genindførselsinstrument |
| EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US5786464C1 (en) * | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| GB9502879D0 (en) | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
| PL328730A1 (en) * | 1996-02-22 | 1999-02-15 | Merck & Co Inc | Synthetic hiv genes |
| US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| EP0991771A2 (en) * | 1997-03-06 | 2000-04-12 | Klaus Überla | Lentivirus based vector and vector system |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| AU2487300A (en) * | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| AU2221600A (en) * | 1998-12-31 | 2000-07-31 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| AP1674A (en) * | 1999-11-16 | 2006-10-30 | Geneart Ag | The genome of the HIV-1 inter-subtype (C/B') and use thereof. |
| CA2393861A1 (en) * | 1999-12-17 | 2001-06-21 | Merck & Co., Inc. | Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef |
| US6656706B2 (en) * | 1999-12-23 | 2003-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes |
| AU784679B2 (en) * | 1999-12-23 | 2006-05-25 | International Aids Vaccine Initiative | Improvements in or relating to immune responses to HIV |
| DE60026199T2 (de) * | 2000-05-18 | 2006-11-23 | Geneart Ag | Synthetische Gene für gagpol und deren Verwendungen |
| JP5052732B2 (ja) * | 2000-08-14 | 2012-10-17 | アメリカ合衆国 | 遺伝的免疫化のための免疫原性を強化するＨＩＶＥｎｖ、Ｇａｇ、およびＰｏｌの改変 |
-
2002
- 2002-09-18 MX MXPA04002631A patent/MXPA04002631A/es active IP Right Grant
- 2002-09-18 US US10/490,011 patent/US20070015721A1/en not_active Abandoned
- 2002-09-18 HU HU0402259A patent/HUP0402259A3/hu unknown
- 2002-09-18 EP EP10180900A patent/EP2322626A1/en not_active Ceased
- 2002-09-18 JP JP2003528849A patent/JP4601956B2/ja not_active Expired - Fee Related
- 2002-09-18 AU AU2002362368A patent/AU2002362368B2/en not_active Ceased
- 2002-09-18 CN CNB028230876A patent/CN100392085C/zh not_active Expired - Fee Related
- 2002-09-18 IL IL16080902A patent/IL160809A0/xx unknown
- 2002-09-18 PL PL370359A patent/PL207168B1/pl not_active IP Right Cessation
- 2002-09-18 CA CA002461056A patent/CA2461056A1/en not_active Abandoned
- 2002-09-18 EP EP02798748A patent/EP1427826B1/en not_active Expired - Lifetime
- 2002-09-18 WO PCT/EP2002/010592 patent/WO2003025003A2/en not_active Ceased
- 2002-09-18 NZ NZ531814A patent/NZ531814A/en not_active IP Right Cessation
- 2002-09-18 BR BR0212619-2A patent/BR0212619A/pt not_active IP Right Cessation
- 2002-09-20 AR ARP020103561A patent/AR036566A1/es active IP Right Grant
-
2004
- 2004-03-17 CO CO04025208A patent/CO5560591A2/es not_active Application Discontinuation
- 2004-03-19 NO NO20041157A patent/NO331826B1/no not_active IP Right Cessation
-
2008
- 2008-01-17 US US12/015,756 patent/US20090203144A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ531814A (en) | 2005-10-28 |
| US20090203144A1 (en) | 2009-08-13 |
| WO2003025003A3 (en) | 2003-12-04 |
| CO5560591A2 (es) | 2005-09-30 |
| CN1606624A (zh) | 2005-04-13 |
| US20070015721A1 (en) | 2007-01-18 |
| JP4601956B2 (ja) | 2010-12-22 |
| EP1427826A2 (en) | 2004-06-16 |
| PL370359A1 (en) | 2005-05-16 |
| NO331826B1 (no) | 2012-04-16 |
| AU2002362368B2 (en) | 2006-09-21 |
| EP2322626A1 (en) | 2011-05-18 |
| HUP0402259A3 (en) | 2010-01-28 |
| IL160809A0 (en) | 2004-08-31 |
| HUP0402259A2 (hu) | 2005-01-28 |
| JP2005511019A (ja) | 2005-04-28 |
| MXPA04002631A (es) | 2004-07-08 |
| CA2461056A1 (en) | 2003-03-27 |
| WO2003025003A2 (en) | 2003-03-27 |
| PL207168B1 (pl) | 2010-11-30 |
| EP1427826B1 (en) | 2011-04-20 |
| NO20041157L (no) | 2004-05-19 |
| BR0212619A (pt) | 2004-08-17 |
| CN100392085C (zh) | 2008-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036566A1 (es) | Vacunas para vih 1 | |
| AR050102A1 (es) | Polipeptidos de fusion de vih para la prevencion y /o tratamiento del sida | |
| AU2003290985B2 (en) | West nile virus vaccine | |
| MY136081A (en) | Modified hiv - 1gag p17 peptide and immunogenic composition | |
| US10556929B2 (en) | Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection | |
| HU228705B1 (en) | Chimeric flavivirus vaccines | |
| CR6491A (es) | Composiciones y metodos inmunogenicos de hiv | |
| US11154608B2 (en) | Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes | |
| NO991078L (no) | HIV peptider, antigener, vaksine sammensetninger, immunoassay kit og en metode for Õ pÕvise antistoffer indusert av HIV | |
| US20190030157A1 (en) | Compositions and Methods for Generating an Immune Response to a Flavivirus | |
| AR041764A1 (es) | Vacuna basada en polinucleotidos y proteinas derivados del vih | |
| Sato et al. | High-level expression of the Japanese encephalitis virus E protein by recombinant vaccinia virus and enhancement of its extracellular release by the NS3 gene product | |
| CN102711817A (zh) | 基于dna疫苗和嵌合体病毒的诱导抗登革热病毒的免疫应答的方法、试剂盒、质粒和组合物 | |
| Ondondo et al. | Immunisation with recombinant modified vaccinia virus Ankara expressing HIV‐1 gag in HIV‐1‐infected subjects stimulates broad functional CD4+ T cell responses | |
| US20050196411A1 (en) | Immunogenic HIV compositions and related methods | |
| Hill et al. | The Cellular Immune Response | |
| JPH03271233A (ja) | ウイルスエンベロープ糖タンパク質及びその糖タンパク質の中和エピトープに対応するペプチドの間の相乗作用による、ウイルス性感染に対する防御の誘発 | |
| EP1534846A1 (en) | Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines | |
| MY131949A (en) | Vaccines | |
| JP2024527039A (ja) | ジカウイルスに対する免疫応答を誘導するための組換え抗原 | |
| ZA200404205B (en) | Hiv-1 subtype isolate regulatory/accessory genes and modifications and derivatives thereof | |
| AR130835A1 (es) | Péptidos natriuréticos de acción prolongada y usos de estos | |
| US20110165190A1 (en) | Compositions and Methods for Immunizing Against Immunodeficiency Viruses | |
| Gairin et al. | Expression in yeast of a cDNA clone encoding a transmembrane glycoprotein gp41 fragment (aa 591–642) bearing the major immunodominant domain of human immunodeficiency virus | |
| AU2023362558A1 (en) | Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of denv, zikv and yfv, inducing protective cd8+ t-cell immunity in a host |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |